<DOC>
	<DOCNO>NCT01839175</DOCNO>
	<brief_summary>Primary Series Primary objectives - To demonstrate concomitant administration hexavalent vaccine meningococcal serogroup C conjugate vaccine non inferior administration hexavalent vaccine without MenC vaccine concomitantly term seroprotection rate hepatitis B one month third dose hexavalent vaccine - To demonstrate concomitant administration MenC vaccine hexavalent vaccine induces acceptable response MenC term seroprotection rate ( SPR ) one month second dose MenC Booster Primary objectives - To describe immunogenicity booster dose hexavalent vaccine meningococcal group ACWY conjugate ( MenACWY ) vaccine either co-administered 12 month age give separately .</brief_summary>
	<brief_title>Concomitant Administration New Hexavalent Vaccine With Meningococcal Serogroup C Conjugate Vaccine Healthy Infants During Primary Series Immunisation Followed Booster Vaccination</brief_title>
	<detailed_description>Primary Series Secondary objectives - To describe antibody response hexavalent vaccine antigens one month third dose hexavalent vaccine give concomitantly MenC - To describe antibody response MenC vaccine MenC vaccine give concomitantly hexavalent vaccine , one month first second dose MenC vaccine - To describe safety profile hexavalent vaccine injection give concomitantly MenC vaccine Booster Secondary objectives - To describe antibody ( Ab ) persistence 12 month age hexavalent valence follow 3-dose primary vaccination 2 , 3 4 month age ( prior administration booster dose ) - To describe safety booster dose hexavalent vaccine meningococcal group ACWY conjugate ( MenACWY ) vaccine either co-administered 12 month age give separately .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy infant 46 74 day age ( inclusive ) Born full term pregnancy ( ≥37 week ) and/or birth weight≥2.5 kg Subject 's parent ( ) legal representative able comply study procedure Participation another clinical study investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede study vaccination Previous vaccination diphtheria , tetanus , pertussis , hepatitis B , poliomyelitis , Haemophilus influenzae type b , meningococcal , pneumococcal , rotavirus infection Know suspect congenital , hereditary acquire immunodeficiency History seizures encephalopathy Known thrombocytopenia Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular injection Chronic illness could interfere trial conduct completion Known suspect hypersensitivity study vaccine ' active substance excipients history lifethreatening reaction vaccine ( ) contain substance study vaccine Contraindication study vaccine Known personal maternal history hepatitis B hepatitis C seropositivity History diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B , Haemophilus influenzae type b meningococcal serogroup C infection Receipt immune globulin , blood bloodderived product , immunosuppressive drug , systemic corticosteroid since birth Identified natural adopt child investigator employee direct involvement current study .</criteria>
	<gender>All</gender>
	<minimum_age>46 Days</minimum_age>
	<maximum_age>76 Days</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>